Patient P-01357
Synthetic patientNBL-101 · Day 96 · 25–34 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
22%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 30 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 30.
Primary contributors, last 14 days
- Toxicity-9
- Treatment adherence+5
- Inflammatory activity-4
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion16.5/100
worsening · +3.7 vs previous 14 d
Toxicity
Blood9.1/100
improving · -6.4 vs previous 14 d
Sleep quality
Wearable72/100
worsening · -4.2 vs previous 14 d
Energy level
Daily log6.9/10
stable · -0.1 vs previous 14 d
Stress level
Daily log2.7/10
stable · +0.0 vs previous 14 d
Steps
Wearable5,677
stable · -28 vs previous 14 d
Adherence
Companion82.6 %
stable · -2.0 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 69 from the failing basin, 47 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
Main detractors to watch
- Low microbial diversityhidden · steering -7.7
- Bacteroides fragilis elevatedhidden · steering -7.4
- Simple carbohydratesperturbation · steering -3.2
- Dietary driftperturbation · steering -2.6
- Simple carbohydratesdetractor · GI +1.8 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Simple carbohydrates+1.8detractor · 76%
- Spicy / capsaicin-0.9no signal · 28%
- Dietary fat load-0.6no signal · 20%
- Histamine load+0.3no signal · 15%
- Alcohol+0.3no signal · 15%
- Insoluble fibre+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 2.9 · butyrate capacity 63/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 60 ms
- Sleep
- 7.7 h
- Steps
- 5,274
- Resting HR
- 72 bpm
Daily log: GI score 17, nutritional resilience 64, adherence 83.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01773 | 43% | S05 | AD-05 | improved | 27 |
| P-01483 | 36% | S14 | AD-05 | no change | 35 |
| P-01377 | 35% | S11 | AD-05 | no change | 42 |
| P-01679 | 32% | S12 | AD-05 | no change | 39 |
| P-01848 | 32% | S05 | AD-05 | no change | 23 |
| P-01541 | 31% | S09 | AD-05 | no change | 43 |
| P-01804 | 23% | S19 | AD-05 | improved | 61 |
| P-01313 | 38% | S01 | BR-03 | improved | 32 |
| P-01450 | 36% | S09 | BR-03 | no change | 36 |
| P-01350 | 30% | S19 | BR-03 | no change | 34 |
| P-01468 | 29% | S06 | BR-03 | no change | 41 |
| P-01689 | 28% | S13 | BR-03 | no change | 50 |